Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.
about
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasisAge-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels(-)-Phenserine attenuates soman-induced neuropathologySynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholNeural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor DrugsNeurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampusNF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease.Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment.Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases.Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy.Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse.
P2860
Q27024824-EFCC115C-03C8-4421-A448-D7744E24466AQ28488088-4518BD7E-8EE2-402F-91F8-EA0D6543DBE0Q28539914-30445A96-4E03-4A0E-8637-CB8A916CB411Q28818062-A210C63D-A01C-4B8F-B984-D152199EFE4FQ30659307-03349C6B-C5B8-423D-AB80-A8AEC5680C5BQ34575780-45BA0724-520E-41E5-9336-8C067E2DBF42Q34761829-BA3C421C-67D0-47FE-9B03-7DDD9955D5DFQ36632979-549FC88E-4FCD-48CC-A2CA-D71F8F91CACDQ36727886-81057281-72CC-40CB-9CCE-8ADE18CFB3E1Q38099889-21A1CDB1-66C2-4006-AB31-F4A0D4C2E840Q38289739-4230ED6B-0936-46D7-96DE-016AFB428280Q38864839-8FCFE0F2-33C2-414F-AB91-2582E9C1B319Q39022532-7DBBBC28-A8F2-4E8E-B223-4236ADC8A495Q42344346-C0F6F4DB-C710-46F5-8E7B-3979D87C2709Q42643645-CEE49C01-6D90-4A84-B28D-328689B97826Q47222390-D72C2D52-7F8A-462F-8C78-E66CE3B0A7C3Q55418661-EFA90374-AB28-4A54-8B6C-49E2A87BD454
P2860
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@ast
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@en
type
label
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@ast
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@en
prefLabel
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@ast
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@en
P2093
P2860
P356
P1476
Posiphen as a candidate drug t ...... nd pharmacokinetics in humans.
@en
P2093
Catherine Pan
Maria L Maccecchini
Mee Young Chang
Nigel H Greig
Varghese John
P2860
P304
P356
10.1136/JNNP-2012-302589
P407
P577
2012-07-11T00:00:00Z